| Symbol | IMMP |
|---|---|
| Name | IMMUTEP LTD |
| Sector | HEALTH CARE |
| Region | Oceania |
| Industry | Pharmaceutical Preparations |
| Address | LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE, SYDNEY,, C3 NSW 2000 |
| Telephone | 612 8315 7003 |
| Fax | — |
| — | |
| Website | https://www.immutep.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001506184 |
| Description | Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3s unique ability to stimulate or suppress the immune response. Immuteps lead clinical candidate, eftilagimod alpha (efti), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer. Additional info from NASDAQ: |
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
Read moreImmutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
Read moreImmutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP
Read moreIMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
Read moreIMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
Read moreINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
Read more